Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension
NCT01756430 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 238
Last updated 2014-01-14
Summary
The aim of present study is to evaluate the efficacy and safety of Carvedilol SR versus Carvedilol IR in Patients With Essential Hypertension
Conditions
Interventions
- DRUG
-
Carvedilol SR 32mg, QD
* Carvedilol SR 32mg QD for 4 weeks * With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks.
- DRUG
-
Carvedilol SR 64mg, QD
* Carvedilol SR 64mg QD for 4 weeks * With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks.
- DRUG
-
Carvedilol IR 25mg, QD
* Carvedilol IR 25mg QD for 4 weeks * With the others investigation product placebo 2 capsules and 1 tablet QD for 4 weeks.
- DRUG
-
Carvedilol IR 25mg, BID
* Carvedilol IR 25mg BID for 4 weeks * With the others investigation product placebo 2 capsules QD for 4 weeks.
Sponsors & Collaborators
-
Chong Kun Dang Pharmaceutical
lead INDUSTRY
Principal Investigators
-
Soon Kill Kim · The Hanyang Universitiy Guri Hospital
-
Sang-Hyun Ihm · The Catholic University of Korea Bucheon St.Mary's Hospital
-
Sang Hong Haek · The Catholic University of Korea, Seoul St. Vincent's Hospital
-
Jin-Bae Kim · Kyunghee University Medical Center
-
Dong Woon Jeon · National Health Insurance Service Ilsan Hospital
-
Chang-Wook Nam · Keimyung University, Donsan Hospital
-
Dong-Ju Choi · Seoul National University Bundang Hospital
-
Min Su Hyon · Soon Chun Hyang University Hospital
-
Young Jin Choi · Sejong General Hospital
-
Hyuck Moon Kwon · Gangnam Severance Hospital
-
Geu Ru Hong · Severance Hospital
-
Byung-Su Yoo · Wonju Severance Christian Hospital
-
Ji-Hyun Lim · Jesus hospital
-
Young Keun Ahn · Chonnam National University Hospital
-
Jin Ho Shin · Hanyang University Seoul Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-12-31
- Primary Completion
- 2013-09-30
- Completion
- 2013-09-30
Countries
- South Korea
Study Locations
More Related Trials
-
Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension
NCT02145104 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D956 in Healthy Adults
NCT06281132 ·Status: COMPLETED ·Phase: PHASE1
-
Phase III Study to Evaluate the Efficacy and Safety of AD-209
NCT06348576 ·Status: RECRUITING ·Phase: PHASE3
-
A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension
NCT02206165 ·Status: UNKNOWN ·Phase: PHASE2
-
Study to Investigate the Influence of CKD-519 on 24-h Ambulatory Blood Pressure in Healthy Adult Volunteers
NCT02916901 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension
NCT01122251 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
NCT06643819 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy
NCT02368652 ·Status: COMPLETED ·Phase: PHASE3
-
Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.
NCT01541189 ·Status: COMPLETED ·Phase: PHASE4
-
A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828
NCT05834595 ·Status: COMPLETED ·Phase: PHASE1
-
A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension
NCT07116863 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy
NCT05878561 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of AD-209
NCT05631990 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg
NCT01918358 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy
NCT02368665 ·Status: COMPLETED ·Phase: PHASE3
-
Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-828 in Healthy Subjects
NCT05540912 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
NCT00280540 ·Status: COMPLETED ·Phase: PHASE4
-
Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients
NCT01928628 ·Status: COMPLETED ·Phase: PHASE3
-
Candesartan Effect in Second Stage Arterial Hypertension
NCT00621153 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Characteristics and Medication Satisfaction of Kanarb Tablet in Korean Hypertensive Patient(Kanarb-Hypertension Epidemiology Medication Satisfaction Study)
NCT02394392 ·Status: COMPLETED
-
Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-341 in Healthy Subjects
NCT05571813 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension
NCT01303783 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of AD-224
NCT06291207 ·Status: RECRUITING ·Phase: PHASE3
-
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D958 in Healthy Adults
NCT05921435 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia
NCT01918332 ·Status: COMPLETED ·Phase: PHASE3